Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer

被引:205
|
作者
Chollet, P
Amat, S
Cure, H
de Latour, M
Le Bouedec, G
Mouret-Reynier, MA
Ferriere, JP
Achard, JL
Dauplat, J
Penault-Llorca, F
机构
[1] Ctr Jean Perrin, Bur Rech Clin, F-63011 Clermont Ferrand 1, France
[2] INSERM, U484, F-63005 Clermont Ferrand, France
关键词
pathological response; prognostic factor; breast cancer; neoadjuvant chemotherapy;
D O I
10.1038/sj/bjc/6600210
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Only a few papers have been published concerning the incidence and outcome of patients with a pathological complete response after cytotoxic treatment in breast cancer. The purpose of this retrospective study was to assess the outcome of patients found to have a pathological complete response in both the breast and axillary lymph nodes after neoadjuvant chemotherapy for operable breast cancer. Our goal was also to determine whether the residual pathological size of the tumour in breast could be correlated with pathological node status. Between 1982 and 2000, 45 1 consecutive patients were registered into five prospective phase 11 trials. After six cycles, 396 patients underwent surgery with axillary dissection for 277 patients (69.9%). Pathological response was evaluated according to the Chevallier's classification. At a median follow-up of 8 years, survival was analysed as a function of pathological response. A pathological complete response rate was obtained in 60 patients (15.2%) after induction chemotherapy. Breast tumour persistence was significantly related to positive axillary nodes (P=5.10(-6)). At 15 years, overall survival and disease-free survival rates were significantly higher in the group who had a pathological complete response than in the group who had less than a pathological complete response (P=0.047 and P=0.024, respectively). In the absence of pathological complete response and furthermore when there is a notable remaining pathological disease, axillary dissection is still important to determine a major prognostic factor and subsequently, a second non cross resistant adjuvant regimen or high dose chemotherapy could lead to a survival benefit. (C) 2002 Cancer Research UK.
引用
收藏
页码:1041 / 1046
页数:6
相关论文
共 50 条
  • [21] Dedicated breast PET to predict pathological complete response after neoadjuvant chemotherapy for breast cancer
    Fujiwara, M.
    Masumoto, N.
    Sasada, S.
    Kadoya, T.
    Okada, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Prognostic significance of residual micrometastatic axillary involvement with complete pathologic breast response after neoadjuvant chemotherapy for early breast cancer
    Garcia-Torralba, Esmeralda
    Guirao Garcia, Maria Esperanza
    de la Morena Barrio, Pilar
    Ivars Rubio, Alejandra
    Garcia Martinez, Elena
    Garcia Garre, Elisa
    Marin Zafra, Gema
    Alvarez Abril, Beatriz
    Navarro Manzano, Esther
    Ayala de la Pena, Francisco
    CANCER RESEARCH, 2021, 81 (04)
  • [23] Pathological complete response and improved breast conservation rates after primary medical therapy for operable early breast cancer
    Parvanta, L
    Weston, J
    Birch, H
    Topham, C
    Houston, S
    Ball, A
    BRITISH JOURNAL OF SURGERY, 2002, 89 : 85 - 85
  • [24] MRI in diagnosis of pathological complete response in breast cancer patients after neoadjuvant chemotherapy
    Li, Yan-Ling
    Zhang, Xiao-Peng
    Li, Jie
    Cao, Kun
    Cui, Yong
    Li, Xiao-Ting
    Sun, Ying-Shi
    EUROPEAN JOURNAL OF RADIOLOGY, 2015, 84 (02) : 242 - 249
  • [25] Occult breast cancer with pathological complete response to neoadjuvant chemotherapy
    Ren, Ningning
    Liu, Shuo
    Shi, Peng
    Tian, Xingsong
    ASIAN JOURNAL OF SURGERY, 2024, 47 (11) : 4949 - 4951
  • [26] Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer
    Penault-Llorca, Frederique
    Abrial, Catherine
    Raoelfils, Ines
    Cayre, Anne
    Mouret-Reynier, Marie-Ange
    Leheurteur, Marianne
    Durando, Xavier
    Achard, Jean-Louis
    Gimbergues, Pierre
    Chollet, Philippe
    HUMAN PATHOLOGY, 2008, 39 (08) : 1221 - 1228
  • [27] PATHOLOGICAL ASSESSMENT OF RESPONSE TO INDUCTION CHEMOTHERAPY IN BREAST-CANCER
    FELDMAN, LD
    HORTOBAGYI, GN
    BUZDAR, AU
    AMES, FC
    BLUMENSCHEIN, GR
    CANCER RESEARCH, 1986, 46 (05) : 2578 - 2581
  • [28] Primary chemotherapy for operable breast cancer: Incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery
    Rouzier, R
    Extra, JM
    Carton, M
    Falcou, MC
    Vincent-Salomon, A
    Fourquet, A
    Pouillart, P
    Bourstyn, E
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) : 3828 - 3835
  • [29] Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients
    Karatas, Fatih
    Erdem, Gokmen Umut
    Sahin, Suleyman
    Aytekin, Aydin
    Yuce, Deniz
    Sever, Ali R.
    Babacan, Taner
    Ates, Ozturk
    Ozisik, Yavuz
    Altundag, Kadri
    BREAST, 2017, 32 : 237 - 244
  • [30] Pathological complete response is not the best prognostic factor in patients with breast cancer treated by preoperative chemotherapy.
    Honig, A
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S52 - S52